Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.

[1]  S. Gaffen.  Recent advances in the IL-17 cytokine family. , 2011, Current opinion in immunology.

[2]  J. Krueger,et al.  Anti-cytokine therapies for psoriasis. , 2011, Experimental cell research.

[3]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[4]  Yoichiro Iwakura,et al.  Review Functional Specialization of Interleukin-17 Family Members , 2022 .

[5]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[6]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[7]  S. Gaffen.  Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.

[8]  F. Nestle,et al.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.

[9]  R. B. Kjellerup,et al.  Characterization of the interleukin‐17 isoforms and receptors in lesional psoriatic skin , 2009, The British journal of dermatology.

[10]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.